Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients

A Randomized, Double-blind, Double-dummy, Three Period Incomplete Cross-over Study to Evaluate the Safety and Efficacy of Multiple Daily Doses of QAX028 as Compared to Tiotropium Bromide (Positive Control) and Placebo in COPD Patients

This study will assess the bronchodilator effects of multiple doses of QAX028 at two different dose levels when compared to tiotropium and placebo in a COPD population.

Inclusion Criteria:

• Diagnosis of COPD according to GOLD guidelines
• Post-bronchodilator 30%≤FEV1<80% of predicted normal and ost-bronchodilator FEV1/FVC <0.7
• Smoking history of at least 10 pack years

Exclusion Criteria:

• Requiring oxygen therapy on a daily basis
• Exacerbation of airway disease in the 6 weeks prior to screening or between screening and dosing
• Lung reduction surgery
• Respiratory tract infection in the 6 weeks prior to screening
• Significant cardiac history
• History of asthma with onset of symptoms prior to age 40 years
• Active use of certain COPD medications, beta blockers

Other protocol-defined inclusion/exclusion criteria may apply